Unpredicted late-, new-onset thrombocytopenia and hypofibrinogenemia in Fab antivenom-treated rattlesnake envenomation.Toxicon. 2020 Sep; 184:55-56.T
Abstract
The use of Fab antivenom (Crotalidae Polyvalent Immune Fab (Ovine) (CroFab); Boston Scientific) against North American Crotalidae envenomation is associated with the development of late- (≥4 days post-envenomation), new-onset of hematological abnormalities. Although attempts have been made to identify predictive indicators during the acute phase of an envenomation, of patients who are not at-risk of late-, new-onset of hematological abnormalities, there has been at least one prior report of a patient who developed thrombocytopenia that was unpredicted by current indicators. We add three cases of unpredicted, late-, new-onset of hematological abnormalities in patients with Fab-treated rattlesnake bite.
Links
MeSH
Pub Type(s)
Journal Article
Language
eng
PubMed ID
32505639
Citation
Seifert, S A., et al. "Unpredicted Late-, New-onset Thrombocytopenia and Hypofibrinogenemia in Fab Antivenom-treated Rattlesnake Envenomation." Toxicon : Official Journal of the International Society On Toxinology, vol. 184, 2020, pp. 55-56.
Seifert SA, Mascarenas DN, Fullerton L, et al. Unpredicted late-, new-onset thrombocytopenia and hypofibrinogenemia in Fab antivenom-treated rattlesnake envenomation. Toxicon. 2020;184:55-56.
Seifert, S. A., Mascarenas, D. N., Fullerton, L., Warrick, B. J., & Smolinske, S. C. (2020). Unpredicted late-, new-onset thrombocytopenia and hypofibrinogenemia in Fab antivenom-treated rattlesnake envenomation. Toxicon : Official Journal of the International Society On Toxinology, 184, 55-56. https://doi.org/10.1016/j.toxicon.2020.05.026
Seifert SA, et al. Unpredicted Late-, New-onset Thrombocytopenia and Hypofibrinogenemia in Fab Antivenom-treated Rattlesnake Envenomation. Toxicon. 2020;184:55-56. PubMed PMID: 32505639.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Unpredicted late-, new-onset thrombocytopenia and hypofibrinogenemia in Fab antivenom-treated rattlesnake envenomation.
AU - Seifert,S A,
AU - Mascarenas,D N,
AU - Fullerton,L,
AU - Warrick,B J,
AU - Smolinske,S C,
Y1 - 2020/06/04/
PY - 2020/04/07/received
PY - 2020/05/28/revised
PY - 2020/05/31/accepted
PY - 2020/6/9/pubmed
PY - 2020/8/28/medline
PY - 2020/6/8/entrez
KW - Antivenom
KW - Envenomation
KW - Fab
KW - Fibrinogen
KW - Platelets
KW - Rattlesnake
KW - Recurrence
SP - 55
EP - 56
JF - Toxicon : official journal of the International Society on Toxinology
JO - Toxicon
VL - 184
N2 - The use of Fab antivenom (Crotalidae Polyvalent Immune Fab (Ovine) (CroFab); Boston Scientific) against North American Crotalidae envenomation is associated with the development of late- (≥4 days post-envenomation), new-onset of hematological abnormalities. Although attempts have been made to identify predictive indicators during the acute phase of an envenomation, of patients who are not at-risk of late-, new-onset of hematological abnormalities, there has been at least one prior report of a patient who developed thrombocytopenia that was unpredicted by current indicators. We add three cases of unpredicted, late-, new-onset of hematological abnormalities in patients with Fab-treated rattlesnake bite.
SN - 1879-3150
UR - https://www.unboundmedicine.com/medline/citation/32505639/Unpredicted_late__new_onset_thrombocytopenia_and_hypofibrinogenemia_in_Fab_antivenom_treated_rattlesnake_envenomation_
DB - PRIME
DP - Unbound Medicine
ER -